| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA5187408
Max Phase: Preclinical
Molecular Formula: C29H31N3O3
Molecular Weight: 469.59
Associated Items:
Representations
Canonical SMILES: COc1ccc(CC2(CCC(=O)NCCn3ccc4ccccc43)CCC(=O)N2)c2ccccc12
Standard InChI: InChI=1S/C29H31N3O3/c1-35-26-11-10-22(23-7-3-4-8-24(23)26)20-29(16-13-28(34)31-29)15-12-27(33)30-17-19-32-18-14-21-6-2-5-9-25(21)32/h2-11,14,18H,12-13,15-17,19-20H2,1H3,(H,30,33)(H,31,34)
Standard InChI Key: XNSYIOZTLGGOCZ-UHFFFAOYSA-N
Associated Targets(non-human)
Androgen Receptor 5522 Activities
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 469.59 | Molecular Weight (Monoisotopic): 469.2365 | AlogP: 4.59 | #Rotatable Bonds: 9 |
| Polar Surface Area: 72.36 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 2 |
| #RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: | CX Basic pKa: | CX LogP: 3.79 | CX LogD: 3.79 |
| Aromatic Rings: 4 | Heavy Atoms: 35 | QED Weighted: 0.38 | Np Likeness Score: -0.80 |
References
| 1. Xie Y, Tian Y, Zhang Y, Zhang Z, Chen R, Li M, Tang J, Bian J, Li Z, Xu X.. (2022) Overview of the development of selective androgen receptor modulators (SARMs) as pharmacological treatment for osteoporosis (1998-2021)., 230 [PMID:35063736] [10.1016/j.ejmech.2022.114119] |
Source
Source(1):